Viking Therapeutics does not pay cash dividends to its common stockholders. Because the biotechnology corporation is in the clinical stage of development, focusing its financial resources on advancing metabolic and weight-management drug candidates through rigorous clinical trials, it retains all available capital to fund ongoing research and laboratory operations. Income-focused investors seeking dividend yields typically look toward established, cash-generating corporate blue-chips rather than pre-revenue biopharmaceutical innovators.